Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:14:27 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



Q:XOMA - XOMA CORP - http://www.xoma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XOMA - Q0.424.37·26.500.124.78-0.66-2.68.218932125.58  25.58  24.6027.00  13.48May 03Apr 3015 min RT 2¢

Recent Trades - Last 10 of 321
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-30 07:30U:XOMANews ReleaseXOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO(TM) (clindamycin phosphate) Vaginal Gel 2%
2024-04-25 07:30U:XOMANews ReleaseXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
2024-04-24 09:00U:XOMANews ReleaseActym Therapeutics Appoints Thomas Smart as CEO
2024-04-03 09:00U:XOMANews ReleaseXOMA Corporation Announces Closing of Tender Offer
2024-03-21 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends
2024-03-19 16:05U:XOMANews ReleaseXOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
2024-03-08 07:30U:XOMANews ReleaseXOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
2024-02-28 07:30U:XOMANews ReleaseXOMA to Present at Upcoming Investor Conferences in March
2024-02-16 08:00U:XOMANews ReleaseXOMA Enters into Agreement to Acquire Kinnate Biopharma ‚  for Between $2.3352 and $2.5879 in Cash Per Share ‚  Plus a Contingent Value Right
2024-01-18 08:30U:XOMANews ReleaseXOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA ‚ ® Acquisition
2024-01-11 16:05U:XOMANews ReleaseFDA Acceptance of Zevra ¢ € ™s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
2024-01-08 07:30U:XOMANews ReleaseXOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
2024-01-02 07:30U:XOMANews ReleaseXOMA Announces Stock Repurchase Program of up to $50 Million
2023-12-20 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends
2023-12-19 07:30U:XOMANews ReleaseXOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing ‚  from Funds Managed by Blue Owl Capital Backed by VABYSMO ‚ ® Royalties
2023-11-07 07:30U:XOMANews ReleaseXOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
2023-10-31 07:30U:XOMANews ReleaseXOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One ¢ € ™s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
2023-09-25 07:30U:XOMANews ReleaseXOMA Declares Quarterly Preferred Stock Dividends
2023-09-06 07:30U:XOMANews ReleaseXOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-08 07:30U:XOMANews ReleaseXOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy